Draft genome sequence of Muricauda sp. strain K001 isolated from a marine cyanobacterial culture

Autor: Vizzotto, CS, Lopes, FAC, Green, SJ, Steindorff, AS, Walter, JM, Thompson, FL, Krüger, RH

Publikováno v: Vizzotto, CS; Lopes, FAC; Green, SJ; Steindorff, AS; Walter, JM; Thompson, FL; et al.(2018). Draft genome sequence of Muricauda sp. strain K001 isolated from a marine cyanobacterial culture. Genome Announcements, 6(22). doi: 10.1128/genomeA.00451-18. Lawrence Berkeley National Laboratory: Retrieved from: http://www.escholarship.org/uc/item/2527r0xk

© 2018 Vizzotto et al. We report the whole-genome sequence of Muricauda sp. strain K001 isolated from a marine cyanobacterial culture. This genome sequence will improve our understanding of the influence of heterotrophic bacteria on the physiology o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::a59581c248929b1f2422c76a70d84cf3
http://www.escholarship.org/uc/item/2527r0xk

Erratum: Coordinated chemomechanical cycles: A mechanism for autonomous molecular motion (Physical Review Letters (2008) 101 (238101))

Autor: Green, SJ, Bath, J, Turberfield, AJ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::237b7b062b8d75e8a0a7d616e372ffa9
https://doi.org/10.1103/physrevlett.102.139901

Abstract 4843: A next generation sequencing (NGS) genome wide copy number variation (CNV) assay for comparison of circulating tumor cell (CTC) heterogeneity

Autor: Dena Marrinucci, Jessica Louw, Green Sj, Adam Jendrisak, Ryan Dittamore, Mark Landers

Publikováno v: Cancer Research. 75:4843-4843

Background: Analysis of CTCs from patient blood represents a non-invasive method for real time monitoring of disease status. Often, targeted therapies require prior knowledge of a patient's somatic mutational status and overall tumor heterogeneity at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf32e9aa26f14ea2f30c39ae0cf0f687
https://doi.org/10.1158/1538-7445.am2015-4843

A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study

Autor: Earl A. Surwit, David S. Alberts, Darryl L. Wallace, Geoffrey R. Weiss, Edward V. Hannigan, Green Sj, John G. Boutselis

Publikováno v: Gynecologic oncology. 39(3)

Forty-one eligible patients with metastatic or recurrent carcinoma of the uterine cervix received 149 courses of carboplatin. The drug was administered at a starting dosage of 400 mg/m2 IV every 28 days. The overall response rate was 15% (two complet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76e2814e9c2dc9153a79fcbe37f563e7
https://pubmed.ncbi.nlm.nih.gov/2258080

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.